|
Abstract Objective：To analyze the clinical efficacy of irbesartan combined with ammonia amiodarone in treatment of non-valvular paroxysmal atrial fibrillation. Method：76 patients with non-valvular paroxysmal atrial fibrillation admitted into our hospital from June 2011 to June 2013 were randomly divided into treatment group and control group，with 38 cases in each group on average.Patients in the treatment group were treated with irbesartan jointly with ammonia amiodarone，and the control group were treated with ammonia amiodarone.Result：The episodes and duration of atrial fibrillation of the patients in the treatment group after 9 months of treatment were significantly reduced，and the left atrial diameter of the control group was significantly higher than that of the treatment group，and the difference was statistically significant.Sinusrhythm maintenance rate（94.7%） was maintained after treatment，which was significantly better than that of the control group.All patients showed no adverse reactions due to drug administration.Conclusion：Treatment of non-valvular atrial fibrillation using irbesartan combined ammonia amiodarone can maintain sinus rhythm and suppress the enlargement left atrium，with significant efficacy.
|
|
|
|
|
|
